PDF(Pubmed)
Abstract：
UNASSIGNED: The use of immune checkpoint inhibitors (ICI) is associated with cardiovascular (CV) events, and patients with pre-existing autoimmune disease are at increased CV risk.
UNASSIGNED: The aim of this study was to characterize the risk for CV events in patients with pre-existing autoimmune disease post-ICI.
UNASSIGNED: This was a retrospective study of 6,683 patients treated with ICIs within an academic network. Autoimmune disease prior to ICI was confirmed by chart review. Baseline characteristics and risk for CV and non-CV immune-related adverse events were compared with a matched control group (1:1 ratio) of ICI patients without autoimmune disease. Matching was based on age, sex, history of coronary artery disease, history of heart failure, and diabetes mellitus. CV events were a composite of myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, or myocarditis. Univariable and multivariable Cox proportional hazards models were used to determine the association between autoimmune disease and CV events.
UNASSIGNED: Among 502 patients treated with ICIs, 251 patients with and 251 patients without autoimmune disease were studied. During a median follow-up period of 205 days, there were 45 CV events among patients with autoimmune disease and 22 CV events among control subjects (adjusted HR: 1.77; 95% CI: 1.04-3.03; P = 0.0364). Of the non-CV immune-related adverse events, there were increased rates of psoriasis (11.2% vs 0.4%; P < 0.001) and colitis (24.3% vs 16.7%; P = 0.045) in patients with autoimmune disease.
UNASSIGNED: Patients with autoimmune disease have an increased risk for CV and non-CV events post-ICI.
UNASSIGNED: The aim of this study was to characterize the risk for CV events in patients with pre-existing autoimmune disease post-ICI.
UNASSIGNED: This was a retrospective study of 6,683 patients treated with ICIs within an academic network. Autoimmune disease prior to ICI was confirmed by chart review. Baseline characteristics and risk for CV and non-CV immune-related adverse events were compared with a matched control group (1:1 ratio) of ICI patients without autoimmune disease. Matching was based on age, sex, history of coronary artery disease, history of heart failure, and diabetes mellitus. CV events were a composite of myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, or myocarditis. Univariable and multivariable Cox proportional hazards models were used to determine the association between autoimmune disease and CV events.
UNASSIGNED: Among 502 patients treated with ICIs, 251 patients with and 251 patients without autoimmune disease were studied. During a median follow-up period of 205 days, there were 45 CV events among patients with autoimmune disease and 22 CV events among control subjects (adjusted HR: 1.77; 95% CI: 1.04-3.03; P = 0.0364). Of the non-CV immune-related adverse events, there were increased rates of psoriasis (11.2% vs 0.4%; P < 0.001) and colitis (24.3% vs 16.7%; P = 0.045) in patients with autoimmune disease.
UNASSIGNED: Patients with autoimmune disease have an increased risk for CV and non-CV events post-ICI.
摘要：
未经评估：使用免疫检查点抑制剂（ICI）与心血管（CV）事件有关，并且预先存在自身免疫性疾病的患者的CV风险增加。
UNASSIGNED：本研究的目的是描述ICI后已有自身免疫性疾病患者发生CV事件的风险。
UNASSIGNED：这是一项在学术网络内接受ICIs治疗的6,683名患者的回顾性研究。ICI之前的自身免疫性疾病通过图表审查得到证实。将基线特征和CV和非CV免疫相关不良事件的风险与无自身免疫性疾病的ICI患者的匹配对照组(1:1比例)进行比较。匹配是基于年龄，性别,冠状动脉疾病史，心力衰竭史,和糖尿病。心血管事件是心肌梗死的复合，经皮冠状动脉介入治疗,冠状动脉旁路移植术,中风,短暂性脑缺血发作,深静脉血栓形成,肺栓塞,或者心肌炎.使用单变量和多变量Cox比例风险模型来确定自身免疫性疾病和CV事件之间的关联。
未经证实：在502名接受ICIs治疗的患者中，研究了251例患者和251例无自身免疫性疾病的患者。在205天的中位随访期间，自身免疫性疾病患者有45例CV事件,对照组有22例CV事件(校正后HR:1.77;95%CI:1.04~3.03;P=0.0364).在非CV免疫相关不良事件中，自身免疫性疾病患者的银屑病(11.2%vs0.4%;P<0.001)和结肠炎(24.3%vs16.7%;P=0.045)发生率升高。
未经证实：患有自身免疫性疾病的患者在ICI后发生CV和非CV事件的风险增加。
UNASSIGNED：本研究的目的是描述ICI后已有自身免疫性疾病患者发生CV事件的风险。
UNASSIGNED：这是一项在学术网络内接受ICIs治疗的6,683名患者的回顾性研究。ICI之前的自身免疫性疾病通过图表审查得到证实。将基线特征和CV和非CV免疫相关不良事件的风险与无自身免疫性疾病的ICI患者的匹配对照组(1:1比例)进行比较。匹配是基于年龄，性别,冠状动脉疾病史，心力衰竭史,和糖尿病。心血管事件是心肌梗死的复合，经皮冠状动脉介入治疗,冠状动脉旁路移植术,中风,短暂性脑缺血发作,深静脉血栓形成,肺栓塞,或者心肌炎.使用单变量和多变量Cox比例风险模型来确定自身免疫性疾病和CV事件之间的关联。
未经证实：在502名接受ICIs治疗的患者中，研究了251例患者和251例无自身免疫性疾病的患者。在205天的中位随访期间，自身免疫性疾病患者有45例CV事件,对照组有22例CV事件(校正后HR:1.77;95%CI:1.04~3.03;P=0.0364).在非CV免疫相关不良事件中，自身免疫性疾病患者的银屑病(11.2%vs0.4%;P<0.001)和结肠炎(24.3%vs16.7%;P=0.045)发生率升高。
未经证实：患有自身免疫性疾病的患者在ICI后发生CV和非CV事件的风险增加。
